CD274 and neoplasm: At the interim analysis, the combination regimen achieved a statistically significant advantage in terms of PFS and numerical, albeit non-statistically significant, advantage in terms of OS over single-agent PD-L1 inhibitor; notably, in the sub-group analysis, the advantage achieved by the combination was pronounced among patients whose tumor harbored high PD-L1 expression (≥50%), but not among patients with PD-L1 between 1–49%.